Iovance Biotherapeutics (IOVA)
Commercializes TIL cell therapies for melanoma and other solid-tumor settings.
$10.17
vs last close−0.47 (−4.42%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 43 days
EPS estimate
−$0.12
Revenue estimate
$110.1M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.26−$0.36−$0.33−$0.25−$0.18−$0.19−$0.11Pending
Estimate−$0.26−$0.25−$0.29−$0.29−$0.22−$0.19−$0.13−$0.12
Surprise0.0%−44.0%−13.8%+13.8%+18.2%0.0%+17.6%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$73.7M$49.3M$60.0M$67.5M$86.7M$71.4M$99.3MPending
Estimate$72.2M$82.4M$78.3M$82.2M$80.7M$77.8M$87.8M$110.1M
Surprise+2.1%−40.1%−23.5%−17.9%+7.4%−8.2%+13.1%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.02 | — | — |
| Sep 2027 | −$0.06 | — | — |
| Jun 2027 | −$0.07 | — | — |
| Mar 2027 | −$0.09 | — | — |
| Dec 2026 | −$0.10 | — | — |
| Nov 2026 | −$0.12 | — | — |
| Aug 2026 | −$0.13 | −$0.11 | +17.6% |
| May 2026 | −$0.19 | −$0.19 | 0.0% |
| Feb 2026 | −$0.22 | −$0.18 | +18.2% |
| Nov 2025 | −$0.29 | −$0.25 | +13.8% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Oct 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.02 | — | — | $158.0M | — | — | — |
| Sep 2027 | −$0.06 | — | — | $142.0M | — | — | — |
| Jun 2027 | −$0.07 | — | — | $131.5M | — | — | — |
| Mar 2027 | −$0.09 | — | — | $122.2M | — | — | — |
| Dec 2026 | −$0.10 | — | — | $120.7M | — | — | — |
| Nov 5, 2026 | −$0.12 | — | — | $110.1M | — | — | — |
| Aug 6, 2026 | −$0.13 | −$0.11 | +17.6% | $87.8M | $99.3M | +13.1% | +43.1% |
| May 7, 2026 | −$0.19 | −$0.19 | 0.0% | $77.8M | $71.4M | −8.2% | −13.2% |
| Feb 24, 2026 | −$0.22 | −$0.18 | +18.2% | $80.7M | $86.7M | +7.4% | +30.8% |
| Nov 6, 2025 | −$0.29 | −$0.25 | +13.8% | $82.2M | $67.5M | −17.9% | +27.6% |
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Feb 28, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 9, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 24, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 5, 2020 | |||||||
| Feb 25, 2020 | |||||||
| Nov 4, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 27, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 6, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 12, 2018 | |||||||
| Oct 31, 2017 | |||||||
| Aug 1, 2017 | |||||||
| May 1, 2017 | |||||||
| Mar 7, 2017 | |||||||
| Nov 4, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 9, 2016 | |||||||
| Mar 10, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Aug 10, 2015 |